title: [Construction, safety and immunogenicity analysis of attenuated salmonella typhimurium harbouring TGEV DNA vaccine].
abstract: OBJECTIVE
  To study the feasibility of using attenuated Salmonella typhimurium as carrier for oral immunization of TGEV DNA vaccine.
  
  
  METHODS
  The 2.1 Kb fragments of the TGVE SC-H strain S gene that encompasses all the four major antigenic domains were amplified by RT-PCR and cloned into eukaryotic expression vector pVAX1. The recombinant plasmid pVAX-S was transfected into COS7 cellsand the expression of recombinant plasmids was identified by indirect immunofluorscence assay. Then pVAX-S was transformed by electroporation into attenuated Salmonella typhimurium SL7207. The recombinant was screened and designated as SL7207 (pVAX-S). Mouse peritoneal macrophages were infected with SL7207 (pVAX-S), the transcription and expression of S gene were detected by RT-PCR and indirect immunofluorscence. BALB/c mouse were inoculated orally with SL7207(pVAX-S) at dosage of 5 x 10(8), 1 x 10(9) and 2 x 10(9) CFU for safety analysis. In a vaccination test, BALB/c mouse were immunized orally with recombinant bacterium at dosage of 1 x 10(9) CFU, for 3 times and specific serum IgG and intestinal mucosal IgA antibody were detected by indirect ELISA.
  
  
  RESULTS
  Recombinant plasmid pVAX-S was constructed correctly and expressed in COS7 cells. The transcription and expression of S gene were detected after mouse peritoneal macrophages were infected with SL7207 (pVAX-S). The recombinant bacterium was safe to mouse at dosage of 2 x 10(9) CFU. Specific serum IgG and intestinal mucosal IgA antibody against TGEV S protein were detected in SL7207 (pVAX-S) immunized group at 2 weeks post-boosting,and there were significant difference (P < 0.05) in serum IgG and most significant difference (P < 0.01) in intestinal mucosal IgA at 2 weeks after the third immunization, compared with SL7207(pVAX) control group.
  
  
  CONCLUSIONS
  The recombinant Salmonella carrying TGEV S gene DNA vaccines had good immunogenicity and safety in mouse.
authors.affiliation: Laboratory of Animal Infectious Disease and Gene Chip, College of Veterinary Medicine, Sichuan Agricultural University, Ya'an 625014, China. 2008yanghengyh@163.com
authors.forename: Heng
authors.initials: H
authors.lastname: Yang
authors.forename: Jiawen
authors.initials: J
authors.lastname: Liu
authors.forename: Sanjie
authors.initials: S
authors.lastname: Cao
authors.forename: Xiaobo
authors.initials: X
authors.lastname: Huang
authors.forename: Xintian
authors.initials: X
authors.lastname: Wen
mesh_terms: D000818:Animals; D019556:COS Cells; D002522:Chlorocebus aethiops; D005260:Female; D007114:Immunization; D007117:Immunization, Secondary; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012449:Safety; D012480:Salmonella Infections / Q000517:prevention & control; D022562:Salmonella Vaccines / Q000276:immunology* / Q000627:therapeutic use; D012486:Salmonella typhimurium / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology*; D019444:Vaccines, DNA / Q000276:immunology*; D014764:Viral Proteins / Q000276:immunology*
chemical_list: D022562:Salmonella Vaccines; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D014764:Viral Proteins; C064484:spike protein S, Transmissible gastroenteritis virus